Compile Data Set for Download or QSAR
Report error Found 39 Enz. Inhib. hit(s) with all data for entry = 9084
TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439303(US10633348, Compound (A-17))
Affinity DataIC50: 17nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439316(US10633348, Compound (A-12))
Affinity DataIC50: 18nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439318(US10633348, Compound (A-14))
Affinity DataIC50: 27.4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439303(US10633348, Compound (A-17))
Affinity DataIC50: 28nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439304(US10633348, Compound (A-2))
Affinity DataIC50: 28nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetHexokinase-4(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 31nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439309(US10633348, Compound (A-7))
Affinity DataIC50: 33.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439308(US10633348, Compound (A-6))
Affinity DataIC50: 38.4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439303(US10633348, Compound (A-17))
Affinity DataIC50: 45nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439318(US10633348, Compound (A-14))
Affinity DataIC50: 53.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439307(US10633348, Compound (A-5))
Affinity DataIC50: 61.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439308(US10633348, Compound (A-6))
Affinity DataIC50: 63.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439309(US10633348, Compound (A-7))
Affinity DataIC50: 71.7nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439316(US10633348, Compound (A-12))
Affinity DataIC50: 76.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439305(US10633348, Compound (A-3))
Affinity DataIC50: 92nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439307(US10633348, Compound (A-5))
Affinity DataIC50: 100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439304(US10633348, Compound (A-2))
Affinity DataIC50: 100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439319(US10633348, Compound (A-15))
Affinity DataIC50: 116nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439319(US10633348, Compound (A-15))
Affinity DataIC50: 136nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439305(US10633348, Compound (A-3))
Affinity DataIC50: 185nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439304(US10633348, Compound (A-2))
Affinity DataIC50: 253nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 275nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 364nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439306(US10633348, Compound (A-4))
Affinity DataIC50: 382nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439317(US10633348, Compound (A-13))
Affinity DataIC50: 392nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439317(US10633348, Compound (A-13))
Affinity DataIC50: 400nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 487nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439306(US10633348, Compound (A-4))
Affinity DataIC50: 591nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM438001(US10633348, Compound (A-8) | US10633348, Compound ...)
Affinity DataIC50: 889nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439314(US10633348, Compound (A-18))
Affinity DataIC50: 1.75E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439303(US10633348, Compound (A-17))
Affinity DataIC50: 3.38E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439314(US10633348, Compound (A-18))
Affinity DataIC50: 6.98E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439312(US10633348, Compound (A-9))
Affinity DataIC50: 7.31E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439315(US10633348, Compound (A-11))
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase BTK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439307(US10633348, Compound (A-5))
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetNuclear receptor subfamily 2 group C member 2(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439313(US10633348, Compound (A-10))
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439315(US10633348, Compound (A-11))
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439312(US10633348, Compound (A-9))
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent

TargetTyrosine-protein kinase HCK(Human)
Dana-Farber Cancer Institute

US Patent
LigandPNGBDBM439313(US10633348, Compound (A-10))
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/10/2021
Entry Details
US Patent